What is the Market's View on Dynavax Technologies Corp (DVAX) Stock's Price and Volume Trends Thursday?

The market has been down on Dynavax Technologies Corp (DVAX) stock recently. DVAX gets a Bearish score from InvestorsObserver Stock Sentiment Indicator.

Dynavax Technologies Corp has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on DVAX!

See Full DVAX Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With DVAX Stock Today?

Dynavax Technologies Corp (DVAX) stock has gained 2.24% while the S&P 500 is down -0.22% as of 12:34 PM on Thursday, Nov 30. DVAX has gained $0.30 from the previous closing price of $13.37 on volume of 537,460 shares. Over the past year the S&P 500 has gained 14.73% while DVAX has gained 15.07%. DVAX earned $0.37 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 37.04. To see InvestorsObserver's Sentiment Score for Dynavax Technologies Corp click here.

More About Dynavax Technologies Corp

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of hepatitis B. Dynavax operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product. Click Here to get the full Stock Report for Dynavax Technologies Corp stock.